|LETTER TO EDITOR
|Year : 2023 | Volume
| Issue : 1 | Page : 36-37
Angioedema with concomitant use of sacubitril/valsartan and enalapril
Logamoorthy Ramamoorthy, Mithin Kumar Balasundaram, Rashmi Kumari
Department of Dermatology and Sexually Transmitted Disease, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
|Date of Submission||20-May-2023|
|Date of Acceptance||06-Jun-2023|
|Date of Web Publication||24-Aug-2023|
Department of Dermatology and Sexually Transmitted Disease, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry 605006
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Ramamoorthy L, Balasundaram MK, Kumari R. Angioedema with concomitant use of sacubitril/valsartan and enalapril. Indian J Drugs Dermatol 2023;9:36-7
|How to cite this URL:|
Ramamoorthy L, Balasundaram MK, Kumari R. Angioedema with concomitant use of sacubitril/valsartan and enalapril. Indian J Drugs Dermatol [serial online] 2023 [cited 2023 Dec 5];9:36-7. Available from: https://www.ijdd.in/text.asp?2023/9/1/36/384284
Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI), which contains the angiotensin receptor blocker valsartan and a neprilysin inhibitor prodrug sacubitril which is converted to an active metabolite. The drug is used in patients with congestive cardiac failure with reduced ejection fraction. The risk of angioedema with sacubitril/valsartan is similar to that with enalapril. The risk of angioedema is high in the black population and when combined with angiotensin-converting enzyme inhibitors (ACEIs) without a washout of 36 h. Herein, we report a case of angioedema over the face following the concomitant use of sacubitril/valsartan and enalapril without a washout period.
A 45-year-old female presented to the emergency department with generalized swelling over the body and breathlessness for 2 days. She was a known case of congestive cardiac failure and hypertension for the past 5 years. The patient was started on frusemide and enalapril in the emergency department and symptomatically improved. After 24 h, anasarca and breathlessness improved, but facial swelling worsened with gross edema of the face, and there was no history of similar episodes in the past. On reviewing the past drug records, the patient took sacubitril/valsartan (50 mg twice daily) and spironolactone for cardiac failure for the past 6 months and regularly continued before the day of admission. Cutaneous examination revealed diffuse swelling of the face with periorbital puffiness and lip swelling suggestive of angioedema of the face [Figure 1]. We advised enalapril and sacubitril/valsartan to be stopped, after which facial swelling significantly improved after 12–24 h [Figure 2]. The patient was changed to beta-blockers for congestive cardiac failure and advised to follow-up regularly.
|Figure 1: Angioedema of the face following the concomitant use of sacubitril/valsartan and enalapril without a washout period|
Click here to view
|Figure 2: Improvement in angioedema within 24 h after stopping sacubitril/valsartan and enalapril|
Click here to view
Sacubitril is a neprilysin inhibitor that increases natriuretic peptides and angiotensin II levels. The natriuretic peptides leads to natriuresis, diuresis and vasodilation. Valsartan blocks angiotensin II leading to vasodilation and aldosterone release. Thus, combining sacubitril with valsartan is beneficial in chronic symptomatic cardiac failure patients. In PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) led to food and drug administration approval sacubitril/valsartan for use in congestive cardiac failure with reduced ejection fraction. After oral administration of sacubitril/valsartan, both drugs dissociate and reach peak concentration simultaneously by about 1.5–4.5 h and reach steady-state level by about 3 days. Generally, angiotensin receptor blockers like valsartan have a low incidence of angioedema, but when combined with sacubitril, the incidence of angioedema is similar to that of ACEIs. Safety guidelines recommend avoiding ARNI concomitantly or within 36 h of the last dose of an ACEI. Also, avoid using ARNI and ACEI in patients with a history of angioedema.
Our patient developed angioedema due to the concomitant use of sacubitril/valsartan and enalapril without a washout period of 36 h. We should take a detailed drug history before administering any new drug to prevent potential harm to patients with congestive cardiac failure. The present case elaborates on a medication error due to a lack of knowledge regarding the new drug interaction in the market.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Sauer AJ, Cole R, Jensen BC, Pal J, Sharma N, Yehya A, et al
. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev 2019;24:167-76.
Owens RE, Oliphant CS Angioedema spotlight: A closer examination of sacubitril/valsartan safety results. J Am Board Fam Med 2017;30:556-7.
Kaplinsky E Sacubitril/valsartan in heart failure: Latest evidence and place in therapy. Ther Adv Chronic Dis 2016;7:278-90.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al
. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, Colvin MM, et al
. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016;68: 1476-88.
[Figure 1], [Figure 2]